Bridgewater-based Insmed Inc., a biopharmaceutical company in the rare disease space, has appointed Sara Bonstein as chief financial officer, effective Friday.
Bonstein will be responsible for leading the company’s financials, including planning and analysis, investor relations, accounting, tax and treasury. She will also serve as a member of the executive committee.
“Sara is an exciting addition to our management team as we continue our efforts to bring ARIKAYCE to patients around the world,” Will Lewis, chairman and CEO of Insmed, said. “In addition to her experience as a public company CFO, she also brings expertise in process improvement and a unique perspective from having served at both large and smaller life sciences companies. Sara is an exceptional talent and her extensive financial and leadership experience will be important as we continue to transform into a global, commercial organization, and we welcome her to the team.”
Prior to Insmed, she was the CFO and chief operaing officer at OncoSec Medical Inc. Before that, she was the CFO, secretary, treasurer and executive vice president at Advaxis Inc., a six sigma champion and black belt at Eli Lilly & Co. and held financial roles at ImClone Systems and Johnson & Johnson. She holds a Masters of Business Administration from Rider University and a Bachelor of Science in finance from The College of New Jersey.
“I am excited to be joining Insmed in the early phase of its international commercial expansion and its ambition to bring this success to other product development opportunities aligns with my background. I look forward to leading Insmed’s financial operations and joining the executive team,” commented Ms. Bonstein. “I am confident my past experience and industry expertise will serve the Company well and further its goal to transform the lives of patients with serious and rare diseases.”
